Adaptimmune Therapeutics PLC SEC filings ADAPY
Adaptimmune Therapeutics PLC has 808 filings in SEC EDGAR's recent list, going back to Oct 2, 2014. Its latest annual report, Form ARS, was filed on Apr 25, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2025, covering the quarter ended Jun 30, 2025. The most recent current report (Form 8-K) was filed on Oct 20, 2025 (listing notice, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Nov 13, 2025 | — |
| S-8 POS | Filing | Oct 28, 2025 | — |
| S-8 POS | Filing | Oct 28, 2025 | — |
| S-8 POS | Filing | Oct 28, 2025 | — |
| POS AM | Filing | Oct 28, 2025 | — |
| S-3 | Shelf registration | Apr 18, 2025 | — |
| S-8 | Employee stock plan registration | Nov 30, 2023 | — |
| S-8 POS | Filing | Jun 29, 2023 | — |
| S-8 POS | Filing | Jun 29, 2023 | — |
| 424B3 | Prospectus | Apr 20, 2023 | — |
| S-4/A | Filing | Apr 18, 2023 | — |
| S-4 | Registration for a merger or exchange | Apr 5, 2023 | — |
| 424B5 | Prospectus supplement | Apr 28, 2022 | — |
| S-3/A | Filing | Apr 21, 2022 | — |
| S-3 | Shelf registration | Apr 8, 2022 | — |
| S-3ASR | Automatic shelf registration | Aug 10, 2020 | — |
| 424B5 | Prospectus supplement | Jun 2, 2020 | — |
| 424B5 | Prospectus supplement | Jun 1, 2020 | — |
| 424B5 | Prospectus supplement | Jan 22, 2020 | — |
| 424B5 | Prospectus supplement | Jan 21, 2020 | — |
| F-6EF | Filing | Aug 30, 2019 | — |
| S-8 | Employee stock plan registration | Aug 30, 2019 | — |
| S-3 | Shelf registration | Aug 30, 2019 | — |
| 424B5 | Prospectus supplement | Sep 5, 2018 | — |
| S-3ASR | Automatic shelf registration | Jul 12, 2018 | — |
| 424B5 | Prospectus supplement | Apr 5, 2017 | — |
| 424B5 | Prospectus supplement | Mar 22, 2017 | — |
| 424B5 | Prospectus supplement | Mar 21, 2017 | — |
| S-3/A | Filing | Sep 8, 2016 | — |
| S-3/A | Filing | Aug 10, 2016 | — |
| F-6EF | Filing | Jul 28, 2016 | — |
| S-3 | Shelf registration | Jul 28, 2016 | — |
| S-8 | Employee stock plan registration | May 7, 2015 | — |
| 424B4 | Prospectus | May 7, 2015 | — |
| F-1MEF | Filing | May 5, 2015 | — |
| F-1/A | Filing | May 1, 2015 | — |
| F-6 | Filing | Apr 27, 2015 | — |
| F-1/A | Filing | Apr 27, 2015 | — |
| F-1 | Registration statement (foreign issuer) | Apr 6, 2015 | — |
Showing 39 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADAPY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Abingdon, Oxfordshire
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621227
- Former names
- Adaptimmune Ltd (until Mar 17, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.